Autres langues FibroBiologics, Inc.

Actions

FBLG

US31573L1052

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 28/05/2024			Varia. 5j.	Varia. 1 janv.
11,99 ^USD	+4,44%		+9,00%	0,00%

14/05	FibroBiologics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
25/04	FibroBiologics, Inc. prévoit de collaborer avec Charles River Laboratories pour fabriquer des sphéroïdes à base de fibroblastes	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

FibroBiologics Announces 2024 Annual Meeting of Stockholders	15/05
FibroBiologics Files 2024 First Quarter Report	14/05
FibroBiologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
FibroBiologics to Present at the BIO International Convention 2024	07/05
FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids	25/04
FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids	25/04
FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office	11/04
FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA	04/04
Fibrobiologics Presents Data from Dermal Fibroblast Spheroid-Based Treatment of Chronic Wounds in A Diabetes Mouse Model At Advanced Wound Care Summit USA	04/04
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus	28/03
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply	20/03
FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment	19/03
FibroBiologics to Present at Advanced Wound Care Summit USA	13/03
FibroBiologics Appoints Ruben A. Garcia as General Counsel	06/03
FibroBiologics, Inc. Appoints Ruben A. Garcia as General Counsel	06/03
FibroBiologics Files 2023 Form 10-K Annual Report	29/02
FibroBiologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Top Premarket Gainers	28/02
FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis Forum	21/02
FibroBiologics, Inc. to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis Forum	20/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues FibroBiologics, Inc.

Actions

FBLG

US31573L1052

Autres langues

Filtres